Stockscreener 앱 받기
10.19
0.49%
-0.05
전일 마감가:
$10.24
열려 있는:
$10.19
하루 거래량:
1,454
Relative Volume:
3.40
시가총액:
$3.64B
수익:
-
순이익/손실:
-
주가수익비율:
-5.3915
EPS:
-1.89
순현금흐름:
-
1주 성능:
-80.40%
1개월 성능:
-80.40%
6개월 성능:
-80.40%
1년 성능:
-80.40%
1일 변동 폭
$10.18
$10.19
1주일 범위
$10.07
$10.45
52주 변동 폭
$10.07
$10.45
Churchill Capital Corp Xi Stock (CCXI) Company Profile
Compare CCXI vs LION, XXI, CCCX, DMII
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CCXI
Churchill Capital Corp Xi
|
10.19 | 3.64B | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
8.09 | 2.31B | 3.13B | -174.20M | -111.20M | -0.6937 |
|
XXI
Twenty One Capital Inc
|
6.40 | 2.01B | 0 | 0 | 0 | 0.00 |
|
CCCX
Churchill Capital Corp X
|
13.66 | 687.84M | 0 | 0 | 0 | 0.00 |
|
DMII
Drugs Made In America Acquisition Ii Corp
|
9.99 | 655.09M | 0 | 0 | 0 | 0.00 |
Churchill Capital Corp Xi Stock (CCXI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-10-11 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-10-11 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-10-08 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-10-08 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-07-07 | 업그레이드 | Stifel | Hold → Buy |
| 2021-05-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-05-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-05-07 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-05-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-05-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-03-02 | 재확인 | H.C. Wainwright | Buy |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2020-10-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-05-27 | 개시 | Wells Fargo | Overweight |
| 2020-05-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-24 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-26 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-26 | 재확인 | Piper Jaffray | Overweight |
| 2019-03-27 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2019-02-11 | 개시 | Piper Jaffray | Overweight |
| 2018-09-07 | 개시 | B. Riley FBR | Neutral |
| 2018-08-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-06-28 | 개시 | Raymond James | Strong Buy |
| 2018-05-02 | 개시 | H.C. Wainwright | Buy |
| 2017-02-21 | 개시 | JMP Securities | Mkt Outperform |
| 2015-05-18 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2013-05-20 | 재확인 | Stifel | Buy |
| 2012-11-14 | 개시 | Stifel Nicolaus | Buy |
모두보기
Churchill Capital Corp Xi 주식(CCXI)의 최신 뉴스
Churchill Capital Corp XI Announces Separate Trading of Shares and Warrants - TradingView
Churchill Capital Corp XI Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing February 9, 2026 - The Manila Times
US FDA Review Team Split On Amgen’s Tavneos Years Before Withdrawal Request - Citeline News & Insights
Asking Amgen to withdraw Tavneos, FDA revisits years-old data issue - BioCentury
Amgen thumbs-down on FDA’s ask, Tavneos sales continue - BioWorld MedTech
Amgen resists FDA request to pull rare disease drug Tavneos from the market - Fierce Pharma
Amgen’s Revenue Gains Outweigh News That FDA Wants Tavneos Pulled From Market - Citeline News & Insights
Amgen Defends Tavneos Benefit-Risk Profile Following FDA Withdrawal Request - Medical Professionals Reference
US FDA Wants Tavneos Pulled From Market, Amgen Declines - Citeline News & Insights
EMA reviewing Amgen’s vasculitis drug over trial ‘data integrity’ - BioWorld MedTech
Rough Price Target for a Promising Quantum Computing Name Working With Nvidia - TheStreet Pro
Churchill Capital Corp X (CCCX) Stock News on Dec. 24, 2025: Infleqtion Quantum SPAC Deal, Latest Catalysts, and What Comes Next - TechStock²
Churchill Capital Corp XI completes $414 million IPO and private placement - Investing.com
Infleqtion Chief Scientist for Quantum Information Dr. Mark Saffman Awarded the John Stewart Bell Prize - 01net
U.S. IPO Weekly Recap: Medline Headlined Final Week Before Christmas - Seeking Alpha
Churchill Capital Corp XI completes $414 million IPO on NASDAQ By Investing.com - Investing.com Nigeria
Churchill Capital Corp XI Announces the Pricing of Upsized $360 Million Initial Public Offering - Yahoo Finance
Another SPAC Boom is Coming; And It’s Stronger than Ever - themiddlemarket.com
Deal Watch: Skadden, Davis Polk, Wachtell, Cravath Lead $20B Deals, as Mega M&A Continues - Law.com
IPO NewsUS IPO Weekly Recap: 2 IPOs come to market, pipeline grows ahead of Thanksgiving holiday week - renaissancecapital.com
Shareholder Alert: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc. - Newsfile
Anca Vasculitis Drug Market Set for Dynamic Rise with Key Players ChemoCentryx, Inc. and Vifor Pharma - openPR.com
Trump, Xi to Talk in Person; CPI on Tap; Oh, Boy, Canada! - TheStreet Pro
First-Ever Bank Rewards to Crypto: JPMorgan to Allow Chase Points Transfer to Coinbase Wallets - Stock Titan
ChemoCentryx Target of Unusually High Options Trading (NASDAQ:CCXI) - 富途牛牛
Immuneering Appoints Dr. Thomas Schall as Chairman of the Board - The Globe and Mail
Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix - TheStreet
Nephrotic Syndrome Pipeline Analysis, 2025 by DelveInsight | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharm - Barchart.com
Latham-Backed Drug Developer's Statements Can't Be Proven False, N.D. Cal. Judge Finds - Law.com
Amgen's ChemoCentryx prevails in investor lawsuit centered on autoimmune drug Tavneos - Fierce Pharma
Pharma Company Beats Investor Suit Over Drug Safety Claims - Law360
ANCA Vasculitis Pipeline 2025: Therapies, MOA Insights, And Key Clinical Trial Updates By Delveinsight By Delveinsight Vifor Pharma, Glaxosmithkline, Amgen, Genentech, Pfizer, Chemocentryx, Biogen - Menafn
Doctored data, protest from trial observers: Lawsuit points to alleged misconduct at Amgen-bought biotech - Fierce Pharma
NVIDIA Certifies AEye's Apollo Lidar for Autonomous Driving Platform, Opening Door to Major Automakers - Stock Titan
Massive Edge AI Deal: Blaize Secures $56M Contract to Power 250K Smart Surveillance Systems in Southeast Asia - Stock Titan
Kodiak Copper: Supporting the Copper Demand for the AI Revolution - The Globe and Mail
DC-Area REIT Saul Centers Keeps Steady Dividend Stream with Latest $0.59 Payout - Stock Titan
25-Year Pharma Veteran Joins aTyr to Launch First New Sarcoidosis Treatment in 70 Years - Stock Titan
Navigator Medicines Appoints Tausif ‘Tosh’ Butt as Chief Executive Officer and Khurem Farooq as Chairman of the Board of Directors - Business Wire
BeiGene Enters Sublease Agreement with ChemoCentryx for Expansion - TipRanks
Bernstein Litowitz Berger & Grossmann LLP Announces Notice of Pendency of Class Action for All Persons and Entities Who Purchased or Otherwise Acquired the Common Stock of ChemoCentryx, Inc. from November 26, 2019 through May 6, 2021, inclusive - Olean Times Herald
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA - Finansavisen
Microscopic Polyangiitis (MPA) Treatment Industry to Witness - openPR.com
Amgen opts to sublease Peninsula space taken in $3.9 billion buyout - The Business Journals
ChemoCentryx (NASDAQ:CCXI) Sees Strong Trading Volume on Analyst Upgrade - 富途牛牛
RA Capital sues ChemoCentryx after biotech company's $3.9 billion sale to Amgen - The Business Journals
About Us | Laser Focus WorldImmuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors - FinancialContent
Amgen sees rare diseases as ‘fourth pillar’ of growth, driven by pair of 2022 deals - BioCentury
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market Foresees Noteworthy US$4.89 Billion Va - PharmiWeb.com
Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading CompaniesACELYRIN, Genentech, ChemoCentryx, Travere Therapeutics, Boehringer Ingelheim, Chinook Therapeutics - PR Newswire
Chemocentryx presents new chemokine CXCR6 receptor antagonists - BioWorld MedTech
Churchill Capital Corp Xi (CCXI) 재무 분석
Churchill Capital Corp Xi (CCXI)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.51%
자본화:
|
볼륨(24시간):